Acadia Pharmaceuticals (ACAD) FCF Margin (2010 - 2026)

Acadia Pharmaceuticals' FCF Margin history runs 17 years deep, the most recent figure standing at 10.73% for Q1 2026.

• On a quarterly basis, FCF Margin rose 241.0% year-over-year to 10.73% in Q1 2026; TTM through Mar 2026 was 10.37%, a 453.0% decrease from a year earlier, with the FY2025 full-year figure at 9.81%, down 660.0% from the prior year.
• FCF Margin advanced to 10.73% in Q1 2026 per ACAD's latest filing, from 18.57% in the prior quarter.
• Across five years, FCF Margin topped out at 36.96% in Q4 2023 and bottomed at 66.1% in Q1 2022.
• The 5-year median for FCF Margin is 8.32% (2025), against an average of 1.25%.
• Across the five-year window, FCF Margin soared 5444 bps in 2023 and sank 3395 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 17.48% in 2022, then jumped by 311 bps to 36.96% in 2023, then sank by 58 bps to 15.38% in 2024, then sank by 221 bps to 18.57% in 2025, then soared by 158 bps to 10.73% in 2026.
• Per Business Quant, the three latest ACAD FCF Margin figures stand at 10.73% (Q1 2026), 18.57% (Q4 2025), and 26.52% (Q3 2025).